← Back to patent-cliff list
Sepetaprost
Tier C — Watch / tradeSepetaprost
-
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PTGFR, PTGER3
Brand：セタネオ, SETANEO
Indications (approved)：Ocular hypertension, Glaucoma
Regional status
US
Phase II
2014-05-01
EU
-
China
-
Japan
Approved
2025-08-25
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sepetaprost?
Approved indications include: Ocular hypertension, Glaucoma.
When does the Sepetaprost patent expire?
No public expiry year is available for Sepetaprost yet; this page updates once verified.
How do I get a quote for Sepetaprost intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01